Anti-EGFR antibody therapies, including cetuximab and panitumumab, have improved the prognosis of patients with CRC, particularly in patients with the wild-type KRAS gene, in which these agents exhibit enhanced efficacy [4–7]. Here, KRAS is linked to colorectal carcinoma.